2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2600

‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2193

“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 2218

1,25D3 Promotes Mineralization of Osteoblasts by Activating C/EBPβ-DKK1 Axis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2409

24-hour Activity Profiling in People Living with Arthritis: Habits Matter

Research Methodology Poster – ARP

9:00AM-11:00AM: Abstract Number: 2524

24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2585

A Comparison of Risk of Ovarian Failure Following Intravenous Cyclophosphamide Therapy in Juvenile versus Adult Systemic Lupus Erythematosus

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2012

A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1968

A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2630

A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2184

A Flexion Contracture Is a Risk Factor for Radiographic Progression and Earlier Need for Arthroplasty in Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 2443

A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 1966

A Genome-Wide Association Study of Copy Number Variations Identifies the Deletion Associated with Efficacy of TNF-Alpha Blocker Therapy in Korean Patients with Rheumatoid Arthritis

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2187

A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: L09

A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2290

A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease

Reproductive Issues In Rheumatic Disorders Poster

1
2
3
…
64
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].